News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Gafchromic films support patient care in oncology
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Digital success is contingent on the way a company organizes itself around technology
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Subscribe To Our Newsletter & Stay Updated
